Relmada Therapeutics, Inc. (RLMD) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $436M · $4.16 · 52-week range $1.52–$8.00

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

Date	Insider	Role	Shares	Price	Value	Source
2026-09-10	Shenouda Maged	officer: Chief Financial Officer	79,800	$4.25	$339,150	SEC Form 4
2026-09-10	TRAVERSA SERGIO	director, officer: Chief Executive Officer	100,000	$4.10	$410,000	SEC Form 4
2026-09-09	Shenouda Maged	officer: Chief Financial Officer	120,200	$4.20	$504,840	SEC Form 4
2026-09-09	TRAVERSA SERGIO	director, officer: Chief Executive Officer	100,000	$4.18	$418,000	SEC Form 4

Financial health

Altman Z-Score 16.50 · Piotroski F-Score 2/9 · Cash $93M · Debt n/a

ClearOcean signal read

ClearOcean's model currently scores RLMD as a watchlist-level signal (7/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — RLMD Form 4
How ClearOcean reads insider activity

Last updated September 22, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.